logo
Plus   Neg
Share
Email

Canopy Growth Launches CBD Beverage Brand Quatreau In The U.S. - Quick Facts

Canadian cannabis company Canopy Growth Corp. (CGC, WEED.TO) announced Tuesday the launch of its Cannabidiol (CBD) beverage brand Quatreau in the high-potential U.S. market. Quatreau will be sold on Canopy's one-stop U.S. e-commerce destination, www.shopcanopy.com.

Quatreau is a premium ready-to-drink CBD-infused sparkling water that delivers natural flavors with zero sugar and only 25 calories.

Quatreau sparkling water contains 20 mg of premium, U.S. grown hemp-based CBD and one of four refreshing flavours - Cucumber + Mint, Passionfruit + Guava, Ginger + Lime and Blueberry + Acai.

With an MSRP of $3.99 per 12-ounce can, Quatreau is a functional zero-sugar drink that delivers a natural, low calorie beverage alternative at an accessible price point.

The stateside launch follows the successful 2020 rollout of Canopy Growth's CBD-infused beverages in Canada, where Quatreau is now the top-selling ready-to-drink CBD beverage.

The launch of Quatreau in America coincides with an astrological event known as the Age of Aquarius - the zodiac's water bearer, which brings us to the cusp of a brand-new age.

To celebrate this serendipitous event, Quatreau has partnered with iconic celebrity astrologist Susan Miller of Astrology Zone on a digital and social campaign.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
Follow RTT